Dublin, April 13, 2017 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Cytogenetics - Technologies, Markets and Companies" to their offering.
This report deals with cytogenetics in a broader sense rather than the classical use mainly to describe the chromosome structure and identify abnormalities related to disease. In the age of molecular biology, it is also referred to as molecular cytogenetics.
The scope of cytogenetics includes several technologies besides fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and multicolor FISH. Molecular cytogenetics includes application of nanobiotechnology, microarrays, real-time polymerase chain reaction (PCR), in vivo imaging, and single molecule detection. Bioinformatics is described briefly as it plays an important role in analyzing data from many of these technologies.
FISH remains the single most important technology in cytogenetics. Several innovations are described of which the most important are single copy FISH, in vivo FISH (imaging of nucleic acids in living cells) and nanotechnology-based FISH. The unique character of peptide nucleic acid (PNA) allows these probes to hybridize to target nucleic acid molecules more rapidly and with higher affinity and specificity compared with DNA probes. PNA-FISH is more suited for rapid diagnosis of infections. RNA-FISH and locked nucleic acids (LNAs), are also described.
Microarray/biochip-based technologies for cytogenetics promise to speed up detection of chromosome aberrations now examined by FISH. Other important genomic technologies are whole genome expression array and direct molecular analysis without amplification. Analysis of single-cell gene expression promises a more precise understanding of human disease pathogenesis and has important diagnostic applications. Optical Mapping can survey entire human genomes for insertions/deletions, which account for a significantly greater proportion of genetic variation between closely-related genomes as compared to single nucleotide polymorphisms (SNPs), and are a major cause of gene defects.
The report includes summary profiles of 69 companies relevant to cytogenetics along with their 80 collaborations. Companies developing innovative technologies as well as those supplying equipment/services/reagents are identified. The report text is supplemented with 27 Tables and 9 figures. Selected 200 references are included in the bibliography.
Key Topics Covered:
Executive Summary
1. Introduction
2. Technologies used for cytogenetics
3. Fluorescent In Situ Hybridization
4. Genomic Technologies relevant to Cytogenetics
5. Molecular Imaging & Single Molecular Detection
6. Role of Nanobiotechnology in Cytogenetics
7. Biomarkers and Cytogenetics
8. Applications of Cytogenetics
9. Cancer Cytogenetics
10. Cytogenetics Markets
11. Companies
12. References
For more information about this report visit http://www.researchandmarkets.com/research/rn867p/cytogenetics
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Genomics


Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
Google Secures Pentagon AI Deal for Classified Projects
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 



